William Blair Investment Management LLC Sells 17,216 Shares of argenex SE $ARGX

William Blair Investment Management LLC cut its holdings in argenex SE (NASDAQ:ARGX – Free Report) by 6.5% during the third quarter, Holdings Channel.com reports. The fund owned 247,401 shares of the company’s stock after selling 17,216 shares during the period. argenex comprises about 0.8% of William Blair Investment Management LLC’s holdings, making the stock its 25th largest holding. William Blair Investment Management LLC’s holdings in argenex were worth $237,204,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Janus Henderson Group PLC raised its position in shares of argenex by 3.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after acquiring an additional 83,568 shares during the last quarter. Jennison Associates LLC lifted its stake in shares of argenex by 3.4% in the 1st quarter. Jennison Associates LLC now owns 237,468 shares of the company’s stock valued at $173,411,000 after purchasing an additional 7,707 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of argenex by 1.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 175,311 shares of the company’s stock valued at $130,277,000 after purchasing an additional 2,579 shares during the period. First Trust Advisors LP boosted its position in shares of argenex by 98.9% in the 1st quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock worth $78,279,000 after purchasing an additional 53,293 shares during the last quarter. Finally, Eagle Health Investments LP boosted its position in shares of argenex by 21.7% in the 1st quarter. Eagle Health Investments LP now owns 76,336 shares of the company’s stock worth $55,744,000 after purchasing an additional 13,606 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Price Performance

Shares of NASDAQ ARGX opened at $960.04 on Monday. The company’s fifty day moving average is $923.87 and its 200-day moving average is $860.78. The stock has a market cap of $60.38 billion, a price-to-earnings ratio of 33.50, a P/E/G ratio of 0.89 and a beta of 0.48. argenex SE has a twelve month low of $661.85 and a twelve month high of $1,072.75.

argenex (NASDAQ:ARGX – Get Free Report) last announced its quarterly earnings results on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.44 by $0.36. argenex had a net margin of 31.66% and a return on equity of 47.70%. The company had revenue of $1.75 billion during the quarter. On average, research analysts anticipate that argenex SE will post 28.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Citizens Jmp lifted their price objective on argenex from $932.00 to $1,200.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 18th. Guggenheim cut their target price on argenex from $1,185.00 to $1,120.00 and set a “buy” rating on the stock in a research note on Friday, October 23rd. DZ Bank restated a “buy” rating on shares of argenex in a report on Friday, October 9th. JPMorgan Chase & Co. restated a “buy” rating on shares of argenex in a research report on Wednesday, August 5th. Finally, Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a research report on Sunday, October 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,163.18.

Check Out Our Latest Research Report on ARGX

argenex Profile

(Free Report)

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.

Featured Articles

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX – Free Report).

Institutional Ownership by Quarter for argenex (NASDAQ:ARGX)

Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.